Codexis Inc. Unveils Presentation on Enzymatic Solutions for Complex Therapeutics and RNA Manufacturing

Reuters

06/03

<a href="https://laohu8.com/S/CDXS">Codexis</a> Inc. Unveils Presentation on Enzymatic Solutions for Complex <a href="https://laohu8.com/S/LENZ">Therapeutics</a> and RNA Manufacturing

Codexis Inc. has released a corporate presentation detailing its latest advancements and business strategies. The company highlights its CodeEvolver® platform, which enables scalable and sustainable enzymatic solutions for the manufacture of complex therapeutics. The presentation outlines Codexis' focus on RNA manufacturing solutions and its foundational business in small molecule manufacturing. Codexis has shown an increasingly positive cash contribution from its newer, higher-margin products, and it plans to achieve cash flow positivity by the end of 2026. The presentation also details Codexis' two paths to revenue: "off-the-shelf" enzyme solutions from existing libraries and custom enzyme evolution. Additionally, Codexis emphasizes its ECO Synthesis toolbox for RNAi therapeutics and its associated revenue streams. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540716595"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540716595\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540716595?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 05:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540716595","market":"nz","top_or_hot":-1,"title":"Codexis Inc. Unveils Presentation on Enzymatic Solutions for Complex Therapeutics and RNA Manufacturing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDXS\">Codexis</a> Inc. Unveils Presentation on Enzymatic Solutions for Complex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and RNA Manufacturing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Codexis Inc. has released a corporate presentation detailing its latest advancements and business strategies. The company highlights its CodeEvolver® platform, which enables scalable and sustainable enzymatic solutions for the manufacture of complex therapeutics. The presentation outlines Codexis' focus on RNA manufacturing solutions and its foundational business in small molecule manufacturing. Codexis has shown an increasingly positive cash contribution from its newer, higher-margin products, and it plans to achieve cash flow positivity by the end of 2026. The presentation also details Codexis' two paths to revenue: \"off-the-shelf\" enzyme solutions from existing libraries and custom enzyme evolution. Additionally, Codexis emphasizes its ECO Synthesis toolbox for RNAi therapeutics and its associated revenue streams. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Codexis Inc. Unveils Presentation on Enzymatic Solutions for Complex Therapeutics and RNA Manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCodexis Inc. Unveils Presentation on Enzymatic Solutions for Complex Therapeutics and RNA Manufacturing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 05:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDXS\">Codexis</a> Inc. Unveils Presentation on Enzymatic Solutions for Complex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and RNA Manufacturing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Codexis Inc. has released a corporate presentation detailing its latest advancements and business strategies. The company highlights its CodeEvolver® platform, which enables scalable and sustainable enzymatic solutions for the manufacture of complex therapeutics. The presentation outlines Codexis' focus on RNA manufacturing solutions and its foundational business in small molecule manufacturing. Codexis has shown an increasingly positive cash contribution from its newer, higher-margin products, and it plans to achieve cash flow positivity by the end of 2026. The presentation also details Codexis' two paths to revenue: \"off-the-shelf\" enzyme solutions from existing libraries and custom enzyme evolution. Additionally, Codexis emphasizes its ECO Synthesis toolbox for RNAi therapeutics and its associated revenue streams. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDXS","symbol_name":"Codexis","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLbmMF0V:1","article_id":"2540716595","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540716595","pubTimestamp":1748900905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Codexis Inc. has released a corporate presentation detailing its latest advancements and business strategies. The company highlights its CodeEvolver platform, which enables scalable and sustainable enzymatic solutions for the manufacture of complex therapeutics. The presentation outlines Codexis' focus on RNA manufacturing solutions and its foundational business in small molecule manufacturing. Codexis has shown an increasingly positive cash contribution from its newer, higher-margin products, and it plans to achieve cash flow positivity by the end of 2026. The presentation also details Codexis' two paths to revenue: \"off-the-shelf\" enzyme solutions from existing libraries and custom enzyme evolution. Additionally, Codexis emphasizes its ECO Synthesis toolbox for RNAi therapeutics and its associated revenue streams. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDXS":"Codexis","BK4121":"生命科学工具和服务"},"translate_title":"Codexis Inc.推出用于复杂治疗和RNA制造的酶解决方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDXS":0.9},"content_text":"Codexis Inc. Unveils Presentation on Enzymatic Solutions for Complex Therapeutics and RNA Manufacturing\n    \n\n        Codexis Inc. has released a corporate presentation detailing its latest advancements and business strategies. The company highlights its CodeEvolver® platform, which enables scalable and sustainable enzymatic solutions for the manufacture of complex therapeutics. The presentation outlines Codexis' focus on RNA manufacturing solutions and its foundational business in small molecule manufacturing. Codexis has shown an increasingly positive cash contribution from its newer, higher-margin products, and it plans to achieve cash flow positivity by the end of 2026. The presentation also details Codexis' two paths to revenue: \"off-the-shelf\" enzyme solutions from existing libraries and custom enzyme evolution. Additionally, Codexis emphasizes its ECO Synthesis toolbox for RNAi therapeutics and its associated revenue streams. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}